Inhibition of endothelial proliferation by the somatostatin analogue SOM230

Robyn L. Adams, Ian P. Adams, Stephen W. Lindow, Stephen Atkin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OBJECTIVE: Somatostatin (SST) modulates exocrine and endocrine secretion, proliferation and apoptosis via five G protein-linked receptors (SSTRs 1-5). Long-acting SST analogues such as Octreotide, and the new analogue SOM230, have been developed for the treatment of neuroendocrine tumours. Octreotide has previously been reported to inhibit endothelial proliferation. We wished to determine if SOM230 is a more potent inhibitor of endothelial cell proliferation than Octreotide. DESIGN: We have determined the expression of SSTRs in proliferating human umbilical vein endothelial cells (HUVECs) in vitro, and determined their response to the somatostatin analogues SOM230 and Octreotide, following vascular endothelial growth factor (VEGF) stimulation. MEASUREMENTS: Quantitative RT-PCR and western blotting were used to determine the expression of SSTRs 1-5 in proliferating HUVECs. These cells were grown in media containing 200 pg/ml VEGF and treated with 10-11 to 10-6 M Octreotide or SOM230. The WST-1 assay was then used to determine the effects of these analogues on HUVEC proliferation. RESULTS: Using quantitative RT-PCR and western blotting, HUVECs were found to express SSTRs 1, 2 and 5. SSTRs 3 and 4 were not detected. Using the WST-1 assay, SOM230 was found to significantly inhibit proliferation by up to 46.0% ± 9.4% (10-6-10 -7 M; P < 0.05), whereas in parallel studies Octreotide failed to inhibit HUVEC proliferation. CONCLUSIONS: The pan SST analogue SOM230 inhibits proliferation of HUVECs, which are unaffected by Octreotide. SOM230 may thus represent a suitable candidate drug for antiangiogenic therapy.

Original languageEnglish
Pages (from-to)431-436
Number of pages6
JournalClinical Endocrinology
Volume61
Issue number4
DOIs
Publication statusPublished - Oct 2004
Externally publishedYes

Fingerprint

Octreotide
Somatostatin
Human Umbilical Vein Endothelial Cells
Cell Proliferation
Vascular Endothelial Growth Factor A
Western Blotting
Polymerase Chain Reaction
Neuroendocrine Tumors
pasireotide
GTP-Binding Proteins
Endothelial Cells
Apoptosis
Drug Therapy
somatostatin receptor type 1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of endothelial proliferation by the somatostatin analogue SOM230. / Adams, Robyn L.; Adams, Ian P.; Lindow, Stephen W.; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 61, No. 4, 10.2004, p. 431-436.

Research output: Contribution to journalArticle

Adams, Robyn L. ; Adams, Ian P. ; Lindow, Stephen W. ; Atkin, Stephen. / Inhibition of endothelial proliferation by the somatostatin analogue SOM230. In: Clinical Endocrinology. 2004 ; Vol. 61, No. 4. pp. 431-436.
@article{55da38b17a2448c79b38db9fbb5c11b1,
title = "Inhibition of endothelial proliferation by the somatostatin analogue SOM230",
abstract = "OBJECTIVE: Somatostatin (SST) modulates exocrine and endocrine secretion, proliferation and apoptosis via five G protein-linked receptors (SSTRs 1-5). Long-acting SST analogues such as Octreotide, and the new analogue SOM230, have been developed for the treatment of neuroendocrine tumours. Octreotide has previously been reported to inhibit endothelial proliferation. We wished to determine if SOM230 is a more potent inhibitor of endothelial cell proliferation than Octreotide. DESIGN: We have determined the expression of SSTRs in proliferating human umbilical vein endothelial cells (HUVECs) in vitro, and determined their response to the somatostatin analogues SOM230 and Octreotide, following vascular endothelial growth factor (VEGF) stimulation. MEASUREMENTS: Quantitative RT-PCR and western blotting were used to determine the expression of SSTRs 1-5 in proliferating HUVECs. These cells were grown in media containing 200 pg/ml VEGF and treated with 10-11 to 10-6 M Octreotide or SOM230. The WST-1 assay was then used to determine the effects of these analogues on HUVEC proliferation. RESULTS: Using quantitative RT-PCR and western blotting, HUVECs were found to express SSTRs 1, 2 and 5. SSTRs 3 and 4 were not detected. Using the WST-1 assay, SOM230 was found to significantly inhibit proliferation by up to 46.0{\%} ± 9.4{\%} (10-6-10 -7 M; P < 0.05), whereas in parallel studies Octreotide failed to inhibit HUVEC proliferation. CONCLUSIONS: The pan SST analogue SOM230 inhibits proliferation of HUVECs, which are unaffected by Octreotide. SOM230 may thus represent a suitable candidate drug for antiangiogenic therapy.",
author = "Adams, {Robyn L.} and Adams, {Ian P.} and Lindow, {Stephen W.} and Stephen Atkin",
year = "2004",
month = "10",
doi = "10.1111/j.1365-2265.2004.02098.x",
language = "English",
volume = "61",
pages = "431--436",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Inhibition of endothelial proliferation by the somatostatin analogue SOM230

AU - Adams, Robyn L.

AU - Adams, Ian P.

AU - Lindow, Stephen W.

AU - Atkin, Stephen

PY - 2004/10

Y1 - 2004/10

N2 - OBJECTIVE: Somatostatin (SST) modulates exocrine and endocrine secretion, proliferation and apoptosis via five G protein-linked receptors (SSTRs 1-5). Long-acting SST analogues such as Octreotide, and the new analogue SOM230, have been developed for the treatment of neuroendocrine tumours. Octreotide has previously been reported to inhibit endothelial proliferation. We wished to determine if SOM230 is a more potent inhibitor of endothelial cell proliferation than Octreotide. DESIGN: We have determined the expression of SSTRs in proliferating human umbilical vein endothelial cells (HUVECs) in vitro, and determined their response to the somatostatin analogues SOM230 and Octreotide, following vascular endothelial growth factor (VEGF) stimulation. MEASUREMENTS: Quantitative RT-PCR and western blotting were used to determine the expression of SSTRs 1-5 in proliferating HUVECs. These cells were grown in media containing 200 pg/ml VEGF and treated with 10-11 to 10-6 M Octreotide or SOM230. The WST-1 assay was then used to determine the effects of these analogues on HUVEC proliferation. RESULTS: Using quantitative RT-PCR and western blotting, HUVECs were found to express SSTRs 1, 2 and 5. SSTRs 3 and 4 were not detected. Using the WST-1 assay, SOM230 was found to significantly inhibit proliferation by up to 46.0% ± 9.4% (10-6-10 -7 M; P < 0.05), whereas in parallel studies Octreotide failed to inhibit HUVEC proliferation. CONCLUSIONS: The pan SST analogue SOM230 inhibits proliferation of HUVECs, which are unaffected by Octreotide. SOM230 may thus represent a suitable candidate drug for antiangiogenic therapy.

AB - OBJECTIVE: Somatostatin (SST) modulates exocrine and endocrine secretion, proliferation and apoptosis via five G protein-linked receptors (SSTRs 1-5). Long-acting SST analogues such as Octreotide, and the new analogue SOM230, have been developed for the treatment of neuroendocrine tumours. Octreotide has previously been reported to inhibit endothelial proliferation. We wished to determine if SOM230 is a more potent inhibitor of endothelial cell proliferation than Octreotide. DESIGN: We have determined the expression of SSTRs in proliferating human umbilical vein endothelial cells (HUVECs) in vitro, and determined their response to the somatostatin analogues SOM230 and Octreotide, following vascular endothelial growth factor (VEGF) stimulation. MEASUREMENTS: Quantitative RT-PCR and western blotting were used to determine the expression of SSTRs 1-5 in proliferating HUVECs. These cells were grown in media containing 200 pg/ml VEGF and treated with 10-11 to 10-6 M Octreotide or SOM230. The WST-1 assay was then used to determine the effects of these analogues on HUVEC proliferation. RESULTS: Using quantitative RT-PCR and western blotting, HUVECs were found to express SSTRs 1, 2 and 5. SSTRs 3 and 4 were not detected. Using the WST-1 assay, SOM230 was found to significantly inhibit proliferation by up to 46.0% ± 9.4% (10-6-10 -7 M; P < 0.05), whereas in parallel studies Octreotide failed to inhibit HUVEC proliferation. CONCLUSIONS: The pan SST analogue SOM230 inhibits proliferation of HUVECs, which are unaffected by Octreotide. SOM230 may thus represent a suitable candidate drug for antiangiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=6344230206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344230206&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2004.02098.x

DO - 10.1111/j.1365-2265.2004.02098.x

M3 - Article

VL - 61

SP - 431

EP - 436

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -